Analyst John Newman of Canaccord Genuity maintained a Buy rating on Seres Therapeutics (MCRB – Research Report), reducing the price target to $14.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
John Newman has given his Buy rating due to a combination of factors surrounding Seres Therapeutics. The company is making significant progress with its SER-155 Phase 2 study, which is focused on addressing bloodstream infections in post-transplant patients. This study has the potential for a quick readout, which could lead to a timely discussion with the FDA for a Phase 3 study design. The breakthrough designation of SER-155 is expected to facilitate faster regulatory discussions, enhancing the prospects for the drug’s development.
Additionally, Seres Therapeutics is actively engaging in partnership discussions, which could further bolster its position. The company’s current cash reserves are projected to support operations into the first quarter of 2026, providing a stable financial runway. Despite some uncertainties around the study design and partnership progress, the potential efficacy of SER-155 in reducing bloodstream infections post-transplant is a promising factor. These elements combined have led John Newman to maintain a Buy rating, albeit with a lowered price target of $14 due to recent market adjustments.
MCRB’s price has also changed dramatically for the past six months – from $0.715 to $8.290, which is a 1059.44% increase.